机构名称：
¥ 1.0
The board of directors (the “ Board ”) of Sino Biopharmaceutical Limited (the “ Company ”, together with its subsidiaries, the “ Group ”) announces that the latest research results of the Phase III clinical study (APOLLO) of Anlotinib Hydrochloride Capsules, a Category 1 innovative drug self-developed by the Group, in combination with Penpulimab Injection for the first-line treatment of advanced肝细胞癌（HCC）在2024年欧洲医学肿瘤学会议委员会（ESMO 2024）上呈现：中位无进展生存期（PFS）为6.9个月，中等的总生存期（OS）为16.5个月，PFS和OS都遇到了预定的终点。这是世界上第二阶段的研究，在该研究中，口服抗血管生成多靶标的小分子酪氨酸激酶抑制剂的组合和免疫疗法药物在晚期HCC的一线治疗中呈阳性。
自愿公告
主要关键词
相关文件推荐
